drugset / Trial / NCT01378364
Phase I Study of AbGn-168H in Healthy Male Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
The aim of the study is to investigate safety, tolerability and pharmacokinetics of single rising doses of AbGn-168H administered by intravenous infusion or subcutaneous injection to healthy male volunteers.
Timeline
- Start
- 2011-06
- Primary completion
- 2011-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neihulizumab | Monoclonal antibody | 125 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 500 ug/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Neihulizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
Indications
No indication recorded.